Weight Loss Drugs Show Promise in Reducing Alcohol Intake

In recent years, medications like semaglutide (marketed as Ozempic and Wegovy) have gained prominence for their effectiveness in treating type 2 diabetes and promoting weight loss. Semaglutide mimics the appetite-suppressing hormone GLP-1. It is known not only for aiding weight loss but also for addressing other health issues, such as knee osteoarthritis pain and reducing dementia risk.

Researchers believe that the drug reduces alcohol cravings by influencing brain areas outside conscious control, making the effect feel effortless. This reduction in alcohol intake mirrors the effects of nalmefene, a drug used for alcohol dependence, offering hope in treating harmful alcohol use, which accounts for 2.6 million deaths annually.

Emerging research suggests that these drugs may also help reduce alcohol cravings, offering a potential new avenue for treating alcohol use disorder (AUD).

Clinical Evidence for Less Drinking

A randomized clinical trial published in JAMA Psychiatry investigated the effects of semaglutide on individuals with AUD. The results indicated that participants who took semaglutide experienced a significant reduction in alcohol intake and cravings. Specifically, semaglutide treatment reduced drinks per drinking day by 41% and weekly alcohol cravings by 40%, compared to a 20% reduction in the control group.

Another study by researchers at University College Dublin analyzed 262 adults, with 188 completing a four-month treatment period. Participants who were regular drinkers saw their average alcohol consumption drop from 23.2 to 7.8 drinks per week, while the overall average intake decreased from 11.3 to 4.3 drinks per week.

Animal Studies

Preclinical studies have further supported semaglutide’s potential in reducing alcohol intake. Research involving rats demonstrated that both acute and repeated administration of semaglutide led to decreased alcohol consumption and prevented relapse-like drinking behavior. The drug appeared to modulate the brain’s reward pathways, particularly in the nucleus accumbens, a region responsible for addiction and pleasure.

The study results confirmed that semaglutide significantly reduces addictive alcohol drinking habits in mice of both genders, with effects varying by dosage. In rats, semaglutide led to a significant reduction in alcohol intake, with no observed sex differences.

Case Reports

A case series reported that six participants taking semaglutide for weight loss experienced significant improvements in AUD symptoms. All showed substantial decreases in their Alcohol Use Disorder Identification Test (AUDIT) scores, indicating reduced alcohol-related problems.

Additionally, a retrospective cohort study of nearly 83,000 obese patients taking semaglutide, compared with those on other anti-obesity medications, demonstrated a 50% lower risk of both the incidence and recurrence of AUD during more than 12 months of follow-up. These results were consistent across various demographics, including gender, age groups, and ethnicity.

Treatment Possibilities

The potential dual benefits of GLP-1 receptor agonists in promoting weight loss and reducing alcohol cravings could revolutionise the treatment of AUD. The popularity and widespread use of drugs like semaglutide may increase the likelihood of their adoption for alcohol-related disorders.

Medical researchers believe that semaglutide’s impact on the brain’s reward and satiety centers, similar to its appetite effects, may contribute to reduced alcohol cravings and consumption. The drug may modulate dopamine levels, which influence pleasure and reward, causing this effect.

Future Outlook

Current studies have limitations, including relatively small sample sizes and short durations. Long-term studies involving diverse populations are essential to fully understand the safety, efficacy, and mechanisms by which these drugs influence alcohol consumption.

Although weight-loss injections are effective and increasingly accessible, they carry potential risks, including digestive issues and rare but serious side effects such as pancreatitis. So far, 85 deaths in the UK have been suspected to be linked to these medications.

Conclusion

Obesity and alcohol addiction are closely associated in many patients. The intersection of metabolic and addiction treatments presents an exciting frontier in medical research. As further studies unfold, GLP-1 receptor agonists like semaglutide and tirzepatide may become integral components of approaches to treating alcohol use disorder, offering hope for more effective interventions.

Source:

Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry [Internet]. 2025 [cited 2025 May 19]; 82(4):395. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811.

By Dr K Shenbaga Vidhya

Disclaimer

Please note that the information available on HealthOdysseyHub is for educational purposes only and, therefore, should not be considered a substitute for professional medical advice, diagnosis, or treatment. While we strive to ensure that the content is accurate and up-to-date, healthcare knowledge is constantly evolving. Therefore, we encourage you to consult with a qualified healthcare professional before making any decisions based on the information found on this site. Additionally, some of the treatments, practices, or approaches discussed on this site may be rooted in alternative or complementary medicine. While we aim to present these perspectives as accurately as possible, they may not always align with conventional medical practices or recommendations.Hence, it is always advisable to approach such content with caution and seek multiple opinions when considering any medical intervention.